Effects of TGF-β on the immune system : implications for cancer immunotherapyDE VISSER, K. E; KAST, W. M.Leukemia. 1999, Vol 13, Num 8, pp 1188-1199, issn 0887-6924Article

Modulation of the immune response and tumor growth by activated RasWEIJZEN, S; VELDERS, M. P; KAST, W. M et al.Leukemia. 1999, Vol 13, Num 4, pp 502-513, issn 0887-6924Article

Fine peptide specificity of cytotoxic T lymphocytes directed against adenovirus-induced tumours and peptide-MHC bindingKAST, W. M; MELIEF, C. J. M.International journal of cancer. 1991, pp 90-94, issn 0020-7136, SUP6Article

T-cell immunotherapy of tumors by adoptive transfer of cytotoxic T lymphocytes and by vaccination with minimal essential epitopesMELIEF, C. J. M; KAST, W. M.Immunological reviews. 1995, Vol 145, pp 167-177, issn 0105-2896Article

Active immunization against cancer cells : Impediments and advancesVELDERS, M. P; SCHREIBER, H; KAST, W. M et al.Seminars in oncology. 1998, Vol 25, Num 6, pp 697-706, issn 0093-7754Article

Notch-1 associates with IKKα and regulates IKK activity in cervical cancer cellsSONG, L. L; PENG, Y; LENDAHL, U et al.Oncogene (Basingstoke). 2008, Vol 27, Num 44, pp 5833-5844, issn 0950-9232, 12 p.Article

Efficient direct priming of tumor-specific cytotoxic T lymphocyte in vivo by an engineered APCSCHOENBERGER, S. P; JONGES, L. E; MOOIJAART, R. J. D et al.Cancer research (Baltimore). 1998, Vol 58, Num 14, pp 3094-3100, issn 0008-5472Article

Identification of HLA-A*0201-restricted CTL epitopes encoded by the tumor-specific MAGE-2 gene productVISSEREN, M. J. W; VAN DER BURG, S. H; VAN DER VOORT, E. I. H et al.International journal of cancer. 1997, Vol 73, Num 1, pp 125-130, issn 0020-7136Article

Decreased expression of signal-transducing ζ chain in peripheral T cells and natural killer cells in patients with cervical cancerKONO, K; RESSING, M. E; BRANDT, R. M. P et al.Clinical cancer research. 1996, Vol 2, Num 11, pp 1825-1828, issn 1078-0432Article

Induction and characterization of cytotoxic T-lymphocytes recognizing a mutated p21ras peptide presented by HLA-A^*0201VAN ELSAS, A; NIJMAN, H. W; VAN DER MINNE, C. E et al.International journal of cancer. 1995, Vol 61, Num 3, pp 389-396, issn 0020-7136Article

Induction of a primary human cytotoxic T-lymphocyte response against a novel conserved epitope in a functional sequence of HIV-1 reverse transcriptaseVAN DER BURG, S. H; KLEIN, M. R; VAN DE VELDE, C. J. H et al.AIDS (London). 1995, Vol 9, Num 2, pp 121-127, issn 0269-9370Article

Allograft tolerance induction in adult mice associated with functional deletion of specific CTL precursorsVAN TWUYVER, E; KAST, W. M; MOOIJAART, R. J. D et al.Transplantation. 1989, Vol 48, Num 5, pp 844-847, issn 0041-1337, 4 p.Article

PBLs of early breast carcinoma patients with a high nuclear grade tumor unlike PBLs of cervical carcinoma patients do not show a decreased TCRζ expression but are functionally impairedNIELAND, J. D; LOVISCEK, K; KAST, W. M et al.Journal of immunotherapy with emphasis on tumor immunology. 1998, Vol 21, Num 4, pp 317-322, issn 1067-5582Conference Paper

Autoantibodies to p53 in ovarian cancer patients and healthy women : a comparison between whole p53 protein and 18-mer peptides for screening purposesVENNEGOOR, C. J. G. M; NIJMAN, H. W; KENEMANS, P et al.Cancer letters. 1997, Vol 116, Num 1, pp 93-101, issn 0304-3835Article

The use of Epstein-Barr virus-transformed B lymphocyte cell lines in a peptide-reconstitution assay : identification of CEA-related HLA-A*0301-restricted potential cytotoxic T-lymphocyte epitopesBREMERS, A. J. A; VAN DER BURG, S. H; KUPPEN, P. J. K et al.Journal of immunotherapy with emphasis on tumor immunology. 1995, Vol 18, Num 2, pp 77-85, issn 1067-5582Conference Paper

Cytotoxic T lymphocytes against the antigen-processing-defective RMA-S tumor cell lineSIJTS, A. J. A. M; DE BRUIJN, M. L. H; NIELAND, J. D et al.European journal of immunology. 1992, Vol 22, Num 6, pp 1639-1642, issn 0014-2980Article

Peptide selection by MHC class I moleculesSCHUMACHER, T. N. M; DE BRUIJN, M. L. H; Nature (London). 1991, Vol 350, Num 6320, pp 703-706, issn 0028-0836, 4 p.Article

Pretransplantation blood transfusion revisitedVAN TWUYVER, E; MOOIJAART, R. J. D; TEN BERGE, I. J. M et al.The New England journal of medicine. 1991, Vol 325, Num 17, pp 1210-1213, issn 0028-4793Article

Direct binding of peptide to empty MHC class I molecules on intact cells and in vitroSCHUMACHER, T. N. M; HEEMELS, M.-T; NEEFJES, J. J et al.Cell (Cambridge). 1990, Vol 62, Num 3, pp 563-567, issn 0092-8674, 5 p.Article

Association between the cellular p53 and the adenovirus 5 E1B-55kd proteins reduces the oncogenicity of Ad-transformed cellsVAN DEN HEUVEL, S. J. L; VAN LAAR, T; KAST, W. M et al.EMBO journal (Print). 1990, Vol 9, Num 8, pp 2621-2629, issn 0261-4189, 9 p.Article

Eradication of adenovirus E1-induced tumor by E1A-specific cytotoxic T lymphocytesKAST, W. M; OFFRINGA, R; PETERS, P. J et al.Cell (Cambridge). 1989, Vol 59, Num 4, pp 603-614, issn 0092-8674Article

Immunodominance and tumor escapeSCHREIBER, H; WU, T. H; NACHMAN, J et al.Seminars in cancer biology. 2002, Vol 12, Num 1, pp 25-31, issn 1044-579XArticle

Peptide specificity of alloreactive CD4 positive T lymphocytes directed against a major histocompatibility complex class I disparityOSSEVOORT, M. A; DE BRUIJN, M. L. H; VAN VEEN, K. J. H et al.Transplantation. 1996, Vol 62, Num 10, pp 1485-1491, issn 0041-1337Article

Class I MHC-peptide interactions : structural requirements and functional implicationsGREY, H. M; RUPPERT, J; VITIELLO, A et al.Cancer surveys. 1995, Vol 22, pp 37-49, issn 0261-2429Article

Identification of peptide sequences that potentially trigger HLA-A2.1-restricted cytotoxic T lymphocytesNIJMAN, H. W; HOUBIERS, J. G. A; VIERBOOM, M. P. M et al.European journal of immunology. 1993, Vol 23, Num 6, pp 1215-1219, issn 0014-2980Article